Rekah is a public company traded on the Tel Aviv Stock Exchange (REKA). As of February 2015, the company is jointly controlled by FIMI Opportunity Funds (42%) and the Elgrably family (29%) .

FIMI, the leading private equity firm in Israel, has a track record of success spanning over 20 years that includes, to date:

  • 94 investments to date
  • 64 exits with a total value over $5.5B
  • 7 private equity funds
  • Over $6B in assets under management
  • Global top ranking as the most consistent performing fund manager


2023 Acquisition of Moraz Pharma
March 2022- Inauguration of the R&D and Registration Center.
Submission for registration in a central European country of a core product in the field of corticosteroids.
Submission for registration in Israel of several generic products in the field of antibiotics and metabolic diseases.
Acquisition of Tree Of Life Pharma.
Starting marketing a steroid product in the UK.
End of 2021 - Completion of a multi-year investment plan to upgrade the factories and infrastructure in the amount of around NIS 100 million.
Acquisition of the Ora Cream brand, start of production and marketing at Vitamed.
Manufacture of antiseptic and OTC products for Teva Israel.